From Analysis:
Sex-Specific Microglial States in Amyloid vs Tau Pathology and Cognitive Decline
What sex-specific microglial transcriptional states emerge in response to amyloid-beta versus tau pathology in the AD brain, and do these sex-divergent states differentially predict cognitive decline trajectory — implicating X-linked immune gene escapees as key regulators of microglial sex differences in AD?
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Sex-Specific Microglial States
X-Linked Gene Dose Effect"]
B["Perturbation-First Validation
Microglial State Modulation Testing"]
C["Female vs Male Microglial Response
Amyloid and Tau Pathology Models"]
D["Cognitive Decline Trajectory
Sex-Dimorphic Outcome Measurement"]
E["Mechanism Confirmation
X-Chromosome Escape Gene Contribution"]
F["AD Personalized Medicine
Sex-Specific Microglial Targeting"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis dfb32151-9c40-452d-8063-0c57bae5c3d6: Sex-Specific Microglial States in Amyloid vs Tau Pathology and Cognitive Decline
Source basis: Sex-dependent molecular landscape of Alzheimer's disease revealed by large-scale single-cell transcriptomics (Alzheimer's & Dementia, 2025, DOI 10.1002/alz.14476). The stored gap context says: Large-scale single-cell analysis identified sex-dependent molecular landscapes; the paper identified microglial states as a key open question for explaining female-biased AD prevalence.
Primary hypothesis: sex-divergent microglial activation
Skeptic critique for analysis dfb32151-9c40-452d-8063-0c57bae5c3d6: Sex-Specific Microglial States in Amyloid vs Tau Pathology and Cognitive Decline
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Sex-dependent molecular landscape of Alzheimer's disease revealed by large-scale single-cell transcriptomics could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: sex differences can be confounded by age, disease stage, hormone exposure, and cell-state a
Domain expert assessment for analysis dfb32151-9c40-452d-8063-0c57bae5c3d6: Sex-Specific Microglial States in Amyloid vs Tau Pathology and Cognitive Decline
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test sex-divergent microglial activation states and X-linked immune escape genes in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational b
{
"ranked_hypotheses": [
{
"title": "sex-divergent microglial activation states and X-linked immune escape genes as proximal driver in Sex-Specific Microglial States in Amyloid vs Tau Pathology and Cognitive Decline",
"description": "sex-divergent microglial activation states and X-linked immune escape genes should produce a measurable proximal phenotype before late disease pathology. The decisive test is sex-stratified single-nucleus RNA-seq with amyloid/tau pathology labels and longitudinal cognition models.",
"target_gene": "amyloid-beta",
"dimension_scores": {
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!